Semax: Complete Research Review of the Nootropic Neuropeptide
Shop Our Top Compounds
Semax Nootropic Neuropeptide: Complete Research Review
All information presented in this article is for research purposes only. Semax is a research peptide and is not approved by the FDA for human therapeutic use. This article reviews published scientific literature and does not constitute medical advice. Not for human consumption.
Introduction: What Is Semax?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the adrenocorticotropic hormone (ACTH) fragment 4-10, originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and Lomonosov Moscow State University in the 1980s. As a synthetic ACTH analogue, Semaxβs chemical structure is defined by its peptide sequence, which consists of seven amino acids. Unlike the parent ACTH molecule, Semax is completely devoid of hormonal activityβit does not stimulate adrenal cortisol productionβyet retains and amplifies the neurotrophic properties associated with melanocortin peptide fragments.
Since its initial characterization, Semax has become one of the most extensively studied nootropic peptides in the research literature, with over 100 peer-reviewed publications documenting its effects on brain-derived neurotrophic factor (BDNF) expression, monoaminergic neurotransmission, cognitive function, and neuroprotection following ischemic injury. In Russia, it has been approved as a prescription nootropic since the late 1990s and is primarily used for its neuroprotective and cognitive-enhancing properties. Semax has also been used clinically in Russia for the treatment of ischemic stroke, showing improvements in neurological function and recovery in patients following administration, and is used in clinical settings for the management of cerebrovascular conditions and cognitive impairment.
This comprehensive research review examines the current body of evidence surrounding Semax, including its molecular mechanisms of action, preclinical and clinical findings on cognitive enhancement and neuroprotection, pharmacokinetic profile, safety data, and emerging structural analogs. Semax is a focus of ongoing drug discovery efforts for neurodegenerative and cognitive disorders. Whether you are a researcher investigating neurotrophic signaling pathways or exploring peptide-based approaches to brain health, this review consolidates the key findings across decades of Semax research. For broader context on research peptides, visit our BPC-157 Complete Guide to explore another extensively studied bioactive peptide.
Mechanism of Action: How Semax Works at the Molecular Level
Understanding the mechanism of action of Semax requires an appreciation of its multi-target pharmacology. Unlike conventional small-molecule nootropics that typically modulate a single receptor system, Semax engages several interconnected neurotrophic and neurotransmitter pathways simultaneously. Experimental data obtained under specific experimental conditions have demonstrated the neuroprotective activity and neuroprotective effect of Semax in various models, highlighting its multifaceted mechanisms of action.
BDNF Upregulation and TrkB Receptor Signaling
The most well-characterized mechanism of Semax involves the upregulation of brain-derived neurotrophic factor (BDNF), a critical mediator of synaptic plasticity, neuronal survival, and memory consolidation. Research by Dolotov et al. (2006) demonstrated that a single intranasal administration of Semax at 50 ΞΌg/kg in rats produced a 1.4-fold increase in BDNF protein levels in the hippocampus, accompanied by a 1.6-fold increase in TrkB tyrosine phosphorylationβthe primary receptor through which BDNF exerts its effects. At the transcriptional level, exon III BDNF mRNA increased 3-fold and TrkB mRNA increased 2-fold following Semax administration.
Further supporting these findings, Dolotov et al. (2006) showed in a separate study that Semax binds to specific, high-affinity binding sites in the rat basal forebrain with a dissociation constant (KD) of 2.4 Β± 1.0 nM and a BMAX of 33.5 Β± 7.9 fmol/mg protein. Intranasal application at doses of 50 and 250 ΞΌg/kg resulted in rapid increases in BDNF protein levels in the basal forebrain within 3 hours.
Downstream of BDNF/TrkB activation, Semax has been linked to enhanced cAMP/CREB signaling cascades, which regulate the transcription of genes involved in long-term potentiation (LTP), synaptic remodeling, and neuronal differentiation. These findings position Semax as a potent indirect modulator of neuroplasticity via neurotrophic factor regulation.
Dopaminergic and Serotonergic Modulation
Beyond neurotrophic signaling, Semax exerts significant modulatory effects on monoaminergic systems. Eremin et al. (2005) conducted a detailed investigation of Semax’s effects on dopaminergic and serotonergic parameters in rodent striatum. Their findings revealed that Semax administration (0.15 mg/kg, i.p.) produced a significant 25% increase in striatal tissue content of 5-hydroxyindoleacetic acid (5-HIAA), a primary serotonin metabolite. Extracellular 5-HIAA levels gradually increased to 180% of baseline within 1β4 hours.
Notably, while Semax alone did not alter basal dopamine concentrations, it dramatically potentiated the effects of d-amphetamine on extracellular dopamine release and locomotor activity. These results reveal a dual mechanism: direct serotonergic activation combined with modulatory enhancement of dopaminergic tone, which may underlie Semax’s observed effects on attention, motivation, and cognitive processing speed.
Immune and Neuroimmune Modulation
An emerging area of Semax research concerns its effects on neuroimmune crosstalk. Genome-wide transcriptome analysis by Dergunova et al. (2017) demonstrated that in rats with focal cerebral ischemia, Semax significantly altered the expression of genes involved in immune cell signaling, antigen presentation, interferon signaling pathways, and immunoglobulin synthesis. These findings suggest that Semax’s neuroprotective properties may be partially mediated through modulation of the immune response to brain injuryβa mechanism distinct from classical neurotrophic pathways.
Cognitive Enhancement Research: Memory, Learning, and Attention
Semaxβs designation as a nootropic peptide rests on a substantial body of research demonstrating improvements in various domains of cognitive function, from basic associative learning in animal models to attention and memory in human studies. Research suggests Semax has potential therapeutic uses in stroke recovery, ADHD, chronic stress, and Alzheimer’s disease, highlighting its relevance in addressing both cognitive enhancement and neurodegenerative conditions.
Preclinical Findings on Learning and Memory
In the landmark BDNF study by Dolotov et al. (2006), Semax-treated animals showed a distinct increase in the number of conditioned avoidance reactions, a standard measure of associative learning. The researchers proposed that Semax affects cognitive brain functions by modulating the expression and activation of the hippocampal BDNF/TrkB systemβa pathway fundamentally linked to memory encoding and consolidation.
Levitskaya et al. (2021) further demonstrated that Semax administration prevented learning and behavioral deficits caused by neonatal exposure to the SSRI fluvoxamine in rats. In this study, Semax reduced anxiety-like behavior, improved acquisition of food-motivated maze tasks, and normalized brain biogenic amine levels that had been disrupted by early-life serotonergic perturbation. These findings underscore Semax’s capacity to restore cognitive function even under conditions of developmental neurotransmitter imbalance.
Additional preclinical work has shown that Semax prevents learning and memory impairment induced by heavy metal exposure, further supporting its role as a broad-spectrum cognitive protectant in research models.
Attention and Default Mode Network Effects
Research by Neznamov et al. (2018) using resting-state functional magnetic resonance imaging (fMRI) investigated the effects of Semax on the default mode network (DMN) of the brain. The DMN is a network of brain regions active during rest that is implicated in attention regulation, self-referential processing, and cognitive flexibility. The study found that Semax modulated functional connectivity patterns within the DMN, suggesting a neurophysiological basis for the attention-enhancing effects reported in earlier behavioral studies.
Tsai (2007) proposed that Semax’s combined ability to augment central dopamine release, stimulate BDNF synthesis, and improve selective attention makes it a candidate of interest for research into attention-related conditions. The author noted that Semax’s pharmacological profileβparticularly its lack of hormonal activity and favorable safety characteristicsβdistinguishes it from conventional psychostimulant compounds.
Functional Connectivity: Semax vs. Selank
A functional connectomic study by Seredenin et al. (2020) directly compared the whole-brain resting-state functional connectivity effects of the nootropic Semax and the anxiolytic Selank using fMRI. The study found that while both peptides increased BDNF expression, Semax produced greater engagement of prefrontal cortical networks associated with executive function and working memory, whereas Selank preferentially modulated limbic circuits associated with emotional regulation. This dissociation provides valuable neuroimaging evidence supporting the distinct cognitive versus anxiolytic profiles of these two regulatory peptides.
Neuroprotection Research: Stroke Recovery and Brain Injury
Perhaps the most clinically significant area of Semax research involves its neuroprotective effects following ischemic brain injury, particularly in the context of acute stroke and focal ischemia models. Multiple preclinical and clinical studies have investigated Semax as an adjunctive neuroprotective agent for stroke and related cerebrovascular conditions, comparing its efficacy to other drugs used in stroke therapy.
Clinical Evidence in Ischemic Stroke
A controlled clinical trial by Gusev et al. (2001) evaluated the effectiveness of Semax in 30 patients during the acute period of hemispheric ischemic stroke, compared against 80 control patients receiving conventional therapy. Using multiple clinical rating scales, EEG monitoring with mapping, and somatosensory evoked potential analysis, the investigators found that Semax inclusion in intensive stroke therapy accelerated the restoration of neurological functions, with particular benefit for motor recovery. In published clinical protocols, researchers administered 12 mg daily for patients with moderate-severity strokes and 18 mg daily for patients with severe strokes, over treatment courses of 5 and 10 days, respectively.
Neuroprotective Mechanisms in Ischemia Models
Dergunova et al. (2017) performed genome-wide transcriptome analysis of ischemized rat brain cortex tissues following Semax treatment. The analysis detected differentially expressed genes associated with immune response, interferon signaling, cytokine production, and stress response pathways. Semax enhanced antigen presentation signaling and intensified interferon pathway activity while significantly increasing expression of immunoglobulin heavy chain genes after middle cerebral artery occlusion.
Proteomic analysis by Filippenkov et al. (2021) confirmed these findings at the protein level, demonstrating that Semax altered the brain protein expression profile in a rat model of cerebral ischemia-reperfusion in ways consistent with neuroprotection. The peptide modulated proteins involved in cellular stress response, mitochondrial function, and apoptotic signaling.
Oxidative Stress, Reactive Oxygen Species, and Nitric Oxide Pathways
Early work by Bashkatova et al. (2001) investigated whether nitric oxide production and lipid peroxidationβtwo key pathological mechanisms in ischemic brain injuryβwere modulated by Semax. The study demonstrated that Semax reduced oxidative stress markers and attenuated ischemia-related neuronal damage, providing mechanistic support for its use as a neuroprotective agent in cerebrovascular research.
Additional studies on basal forebrain cholinergic neurons by Dolotov et al. (2008) showed that Semax promoted the survival of these vulnerable neuronal populations, which are among the first to degenerate in conditions associated with cognitive decline.
Semax vs. Selank: Nootropic and Anxiolytic Peptide Profiles
Semax and Selank are the two most prominent regulatory peptides to emerge from Russian neuropharmacological research, and their comparison illuminates the diverse potential of synthetic neuropeptides. While both peptides share neurotrophic propertiesβnotably BDNF upregulationβtheir primary functional profiles diverge significantly.
Structurally, Semax is a synthetic peptide whose chemical structure consists of a heptapeptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro), meaning the peptide consists of seven amino acids. This specific molecular configuration is key to its biological activity, stability, and neuroprotective effects. Semax is classified among therapeutic peptides, designed for research and clinical applications targeting cognitive and neurological functions.
Structural and Pharmacological Differences
Semax is derived from the ACTH(4-10) fragment and acts primarily through melanocortin-related pathways, neurotrophic factor stimulation, and monoaminergic modulation. Selank, by contrast, is a synthetic analog of the endogenous immunomodulatory peptide tuftsin and acts through enkephalinase inhibition and GABAergic modulation.
Feature | Semax | Selank |
|---|---|---|
Parent Molecule | ACTH(4-10) | Tuftsin |
Primary Profile | Nootropic / Neuroprotective | Anxiolytic / Immunomodulatory |
BDNF Effect | Strong upregulation | Moderate upregulation |
Neurotransmitter Focus | Dopamine / Serotonin | GABA / Enkephalins |
Brain Networks | Prefrontal / Executive | Limbic / Emotional |
Key Applications | Cognition, stroke recovery | Anxiety, immune modulation |
Research Context for Combined Approaches
Some researchers have investigated the theoretical rationale for combining nootropic and anxiolytic peptide approaches, given the complementary mechanisms of Semax and Selank. The functional connectomic study by Seredenin et al. (2020) demonstrated non-overlapping patterns of brain network modulation, suggesting that the two peptides target distinct aspects of neural function. Explore IronPeak’s full catalog of research peptides to find both Semax and Selank formulations for your investigations.
Research Dosing Protocols in Published Studies
The following information describes dosing parameters used in published preclinical and clinical research studies. This information is provided for research reference only and does not constitute dosage recommendations. Not for human consumption.
In published animal studies, researchers have administered Semax across a range of doses depending on the research application, with dosing protocols and observed effects varying according to specific experimental conditions and supported by experimental data:
Cognitive studies: In published protocols, researchers administered 50β250 ΞΌg/kg intranasally to rats, observing significant BDNF upregulation and enhanced associative learning at the lower end of this range (Dolotov et al., 2006).
Neurochemical studies: Eremin et al. (2005) administered 0.15 mg/kg via intraperitoneal administration to investigate serotonergic and dopaminergic effects.
Pharmacokinetic studies: Shevchenko et al. (2006) used 50 ΞΌg/kg intranasal administration (20 ΞΌL volume) for brain penetration kinetics.
In the clinical stroke study by Gusev et al. (2001), researchers administered Semax intranasally at doses of 12β18 mg/day over 5β10 day treatment courses, with dose selection based on stroke severity.
Research protocols have generally reported rapid onset of central effects, with neurochemical changes detectable within 2β3 hours of intranasal administration and behavioral effects observable within the first session of cognitive testing.
Pharmacokinetics: Intranasal Bioavailability and Brain Penetration
The pharmacokinetic profile of Semax has been characterized primarily through intranasal administration, which is the preferred route in both research and clinical settings due to its ability to bypass the blood-brain barrier (BBB) via the nasal-brain pathway.
Intranasal Brain Penetration
A pivotal pharmacokinetic study by Shevchenko et al. (2006) used tritium-labeled Semax to trace the kinetics of peptide penetration into the brain following intranasal administration in rats. The study demonstrated that 0.093% of the total administered radioactivity per gram was detected in the brain within 2 minutes of intranasal delivery, with 80% of this radioactivity corresponding to intact Semax and the remainder to metabolites.
The peptide undergoes rapid enzymatic degradation, with the C-terminal tripeptide Pro-Gly-Pro (PGP) identified as the predominant metabolite. Notably, PGP itself has been shown to possess biological activity, including immunomodulatory properties, suggesting that Semax’s metabolites may contribute to its overall pharmacological effects.
Serum Half-Life and Metabolism
Research indicates that the serum half-life of Semax exceeds 1 hourβconsiderably longer than the parent ACTH(4-10) fragment, which is rapidly degraded by serum peptidases. This extended stability is attributed to the C-terminal Pro-Gly-Pro modification, which confers resistance to carboxypeptidase-mediated cleavage. After intravenous administration, approximately 0.01% of Semax crosses the blood-brain barrier, reinforcing the advantage of intranasal delivery for central nervous system targeting.
The intranasal route allows Semax to access brain tissue via both the olfactory and trigeminal nerve pathways, bypassing first-pass hepatic metabolism entirely and achieving meaningful CNS concentrations at far lower systemic doses than would be required through parenteral routes.
Safety Profile from Clinical and Preclinical Studies
One of the most notable features of Semax in the research literature is its remarkably favorable safety profile. Across multiple preclinical and clinical investigations, Semax has consistently demonstrated excellent tolerability with minimal adverse effects. As part of peptide quality control in the life sci field, research-grade peptides like Semax undergo rigorous testing for contaminants, including endotoxins, to ensure safety for research and experimental use. quality assurance documentation (quality documentation) are provided to verify the purity, identity, and concentration of these peptides, supporting compliance with research standards.
Clinical Safety Data
In the controlled clinical trial of acute ischemic stroke by Gusev et al. (2001), Semax administered at doses of 12β18 mg/day was well tolerated, with no significant adverse events reported during the treatment period. Published clinical studies in Russia spanning over two decades of use as a prescription medication have reported that intranasal Semax does not cause notable systemic side effects at standard research doses.
Key Safety Characteristics
Research has identified several favorable safety attributes of the Semax peptide:
No hormonal activity: Despite being derived from ACTH, Semax is completely devoid of corticotropic activity and does not stimulate cortisol production or interfere with the hypothalamic-pituitary-adrenal (HPA) axis.
No sedation or muscle relaxation: Unlike many anxiolytic compounds, Semax does not produce sedative effects, motor impairment, or cognitive dulling.
No addiction potential: Published studies have not identified tolerance, dependence, or withdrawal phenomena associated with Semax administration.
No significant organ toxicity: Preclinical safety studies have not reported liver, kidney, or cardiovascular toxicity at research-relevant doses.
Reported Adverse Effects
Minor adverse effects reported in some studies include transient nasal irritation at the site of intranasal administration and occasional mild headache. These effects have generally been described as mild and self-limiting. Researchers should note that the long-term safety profile beyond existing clinical trial durations requires further investigation.
N-Acetyl Semax and Semax Amidate Variants
The success of Semax in research settings has prompted the development of structural analogs designed to enhance specific pharmacokinetic or pharmacodynamic properties. Two notable variants are N-Acetyl Semax and N-Acetyl Semax Amidate (NASA).
N-Acetyl Semax
N-Acetyl Semax incorporates an acetyl group at the N-terminus of the peptide. This modification is hypothesized to enhance metabolic stability by protecting the methionine residue from oxidative degradation and aminopeptidase-mediated cleavage. N-acetylation is a well-established strategy in peptide chemistry for extending biological half-life while preserving receptor-binding properties.
N-Acetyl Semax Amidate (NASA)
N-Acetyl Semax Amidate features both N-terminal acetylation and C-terminal amidationβdual modifications that protect both ends of the peptide from exopeptidase degradation. The C-terminal amide group replaces the free carboxyl group of the terminal proline, conferring additional resistance to carboxypeptidase activity.
Research suggests that these modifications may:
Extend the effective half-life beyond that of standard Semax
Enhance blood-brain barrier penetration due to increased lipophilicity from the amide modification
Improve overall bioavailability by reducing first-pass enzymatic degradation
While these analogs show theoretical promise and are available for research purposes, it should be noted that the peer-reviewed literature on these specific variants is more limited than for the parent Semax molecule. Researchers investigating these compounds are encouraged to review available data carefully. Browse Shop Semax and related analogs in IronPeak’s research catalog.
Current Research Landscape and Future Directions
The Semax research landscape continues to expand, with investigations branching into several promising directions beyond classical nootropic and neuroprotective applications. Semax is a focus of ongoing drug discovery efforts, as researchers explore its potential as a therapeutic agent for neurodegenerative and cognitive disorders. Notably, Semax demonstrates significant neuroprotective activity in various research models, where it has been shown to protect neurons from excitotoxicity, oxidative damage, and apoptosis, further supporting its relevance in both pharmaceutical development and experimental neuroscience.
Neurodegenerative Disease Models
Recent research by Kuznetsova et al. (2022) demonstrated that Semax can prevent the formation of amyloid-beta:copper(II) complexes and exhibits anti-aggregating and protective propertiesβfindings with potential relevance to Alzheimer’s disease research. The peptide’s combined neurotrophic, anti-inflammatory, and anti-aggregating properties make it a subject of interest for researchers studying multiple pathways of neurodegeneration.
Neurodevelopmental Research
Tsai (2007) proposed that Semax’s unique pharmacological profileβBDNF stimulation, dopaminergic modulation, and attention improvement without hormonal side effectsβwarrants investigation in neurodevelopmental research models, particularly those involving BDNF dysfunction.
Gene Expression, Transcriptomic and Proteomic Profiling
Advances in systems biology are enabling more comprehensive characterization of Semax’s effects on gene expression and protein networks. The genome-wide studies by Dergunova et al. (2017) and proteomic analyses by Filippenkov et al. (2021) have revealed that Semax affects hundreds of genes and proteins across multiple functional categories, suggesting biological activity far broader than initially appreciated.
Structural Optimization
Research into modified analogs like N-Acetyl Semax Amidate represents an active area of peptide engineering, aimed at developing compounds with optimized pharmacokinetic profiles for specific research applications. As analytical techniques improve, more detailed structure-activity relationship studies are expected to guide the rational design of next-generation melanocortin-derived neuropeptides.
For researchers interested in exploring Semax alongside other neuroprotective peptides, Iron Peak Peptides offers a comprehensive catalog of research-grade compounds. Visit our Peptide Glossary for definitions of key terms, or explore our BPC-157 Complete Guide for insights into another extensively studied bioactive peptide.
Frequently Asked Questions About Semax Research
What is Semax and how was it developed?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was designed to retain the neurotrophic properties of ACTH fragments while eliminating hormonal activity. Research has identified Semax as a potent nootropic neuropeptide with effects on BDNF signaling, monoaminergic neurotransmission, and neuroprotection.
How does Semax affect BDNF levels in research models?
Published studies have demonstrated that Semax upregulates both BDNF protein and mRNA expression in key brain regions. In rat hippocampus, a single intranasal dose of 50 ΞΌg/kg produced a 1.4-fold increase in BDNF protein and a 3-fold increase in exon III BDNF mRNA (Dolotov et al., 2006). Semax also increased TrkB receptor phosphorylation by 1.6-fold, indicating enhanced neurotrophic signaling activity.
What is the difference between Semax and Selank?
Semax and Selank are both synthetic regulatory peptides but with distinct pharmacological profiles. Semax, derived from ACTH(4-10), primarily demonstrates nootropic and neuroprotective properties with pronounced effects on dopaminergic and serotonergic systems. Selank, derived from the immunomodulatory peptide tuftsin, exhibits primarily anxiolytic effects mediated through GABAergic and enkephalinergic mechanisms. Neuroimaging research shows Semax engages prefrontal executive networks while Selank modulates limbic emotional circuits.
What does research indicate about Semax’s neuroprotective properties?
Multiple preclinical and clinical studies have investigated Semax’s neuroprotective effects. In a controlled clinical trial, Gusev et al. (2001) found that Semax accelerated neurological recovery in acute ischemic stroke patients. Mechanistic studies have shown that Semax modulates immune response genes, reduces oxidative stress markers, and alters protein expression profiles in ischemia-reperfusion models in ways consistent with neuroprotection.
What are N-Acetyl Semax and N-Acetyl Semax Amidate?
These are structurally modified variants of Semax designed for enhanced metabolic stability. N-Acetyl Semax features an acetyl group at the N-terminus for protection against aminopeptidases. N-Acetyl Semax Amidate (NASA) adds C-terminal amidation for dual-end protection against exopeptidases. These modifications are hypothesized to extend half-life, improve bioavailability, and enhance blood-brain barrier penetration, though peer-reviewed data on these specific variants remains more limited than for standard Semax.
Is Semax the same as ACTH?
No. Semax is a synthetic analog of only the 4-10 fragment of ACTH, and it is completely devoid of hormonal activity. Full-length ACTH (39 amino acids) stimulates cortisol production from the adrenal glands, while Semax (7 amino acids) does not affect the HPA axis or cortisol levels. Semax retains only the neurotrophic signaling properties associated with the melanocortin fragment while eliminating endocrine effects.
Conclusion
Semax stands as one of the most thoroughly investigated nootropic neuropeptides in the scientific literature, with research spanning over three decades and encompassing molecular biology, neurochemistry, neuroimaging, and clinical trials. Its multi-mechanism pharmacologyβengaging BDNF/TrkB neurotrophic signaling, dopaminergic and serotonergic modulation, and neuroimmune regulationβprovides a rich foundation for continued investigation into peptide-based approaches to brain health and neuroprotection.
The evidence base supporting Semax’s cognitive-enhancing and neuroprotective effects continues to grow, with recent advances in transcriptomics and proteomics revealing an increasingly complex picture of its biological activity. Structural variants such as N-Acetyl Semax Amidate offer additional avenues for pharmacokinetic optimization, expanding the toolkit available to researchers.
For investigators seeking high-quality research peptides, Iron Peak Peptides provides Semax and related compounds manufactured to rigorous purity standards. Explore our complete research peptide catalog to find the right compounds for your next study, and consult our Peptide Glossary for essential terminology.
Research References
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. βSemax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.β Brain Research, 1117(1), 54-60, 2006. DOI: 10.1016/j.brainres.2006.07.108. PMID: 16996037
Dolotov OV, Karpenko EA, Polenova OA, et al. βSemax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.β Journal of Neurochemistry, 97(Suppl 1), 82-86, 2006. DOI: 10.1111/j.1471-4159.2006.03658.x. PMID: 16635254
Eremin KO, Kudrin VS, Saransaari P, et al. βSemax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotonergic brain systems in rodents.β Neurochemical Research, 30(12), 1493-1500, 2005. DOI: 10.1007/s11064-005-8826-8. PMID: 16362768
Tsai SJ. βSemax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.β Medical Hypotheses, 68(5), 1144-1146, 2007. DOI: 10.1016/j.mehy.2006.07.017. PMID: 16996699
Levitskaya NG, Sebentsova EA, Andreeva LA, et al. βSemax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.β Neuropeptides, 86, 102114, 2021. DOI: 10.1016/j.npep.2020.102114. PMID: 33418449
Gusev EI, Skvortsova VI, Chukanova EI. βEffectiveness of Semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).β Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 101(6), 26-34, 2001. PMID: 11517472
Shevchenko KV, Nagaev IY, Alfeeva LY, et al. βKinetics of Semax penetration into the brain and blood of rats after its intranasal administration.β Bioorganicheskaya Khimiya, 32(1), 64-70, 2006. DOI: 10.1134/S1068162006010062. PMID: 16523722
Dergunova LV, Dmitrieva VG, Filippenkov IB, et al. βSemax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.β Molecular Genetics and Genomics, 292(3), 635-653, 2017. DOI: 10.1007/s00438-017-1297-1. PMID: 28255762
Dmitrieva VG, Povarova OV, Skvortsova VI, et al. βSemax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.β Cellular and Molecular Neurobiology, 30(1), 71-79, 2010. DOI: 10.1007/s10423-009-9260-x. PMID: 19633950
Filippenkov IB, Remizova JA, Dergunova LV, et al. βBrain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion.β International Journal of Molecular Sciences, 22(12), 6179, 2021. DOI: 10.3390/ijms22126179. PMID: 34201112
Bashkatova VG, Koshelev VB, Fadyukova OE, et al. βNovel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia.β Brain Research, 894(1), 145-149, 2001. DOI: 10.1016/S0006-8993(00)03324-2. PMID: 11245825
Seredenin SB, Voronina TA, Gudasheva TA, et al. βFunctional connectomic approach to studying Selank and Semax effects on the default mode network.β Bulletin of Experimental Biology and Medicine, 169(1), 71-75, 2020. DOI: 10.1007/s10517-020-04822-z. PMID: 32342318
Neznamov GG, Kravtsova EN, Davydova IA, et al. βEffects of Semax on the default mode network of the brain.β Bulletin of Experimental Biology and Medicine, 165(5), 653-656, 2018. DOI: 10.1007/s10517-018-4230-y. PMID: 30225715
Kuznetsova EA, Mineev KS, Nadezhdin KD, et al. βSemax, a synthetic regulatory peptide, affects copper-induced AΞ² aggregation and amyloid formation in artificial membranes.β International Journal of Molecular Sciences, 23(4), 2048, 2022. DOI: 10.3390/ijms23042048. PMID: 35216161
Research Disclaimer
The information contained in this article is intended for educational and research reference purposes only. Semax is sold exclusively as a research chemical and is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or medical condition. The content presented here summarizes findings from published peer-reviewed research and does not constitute medical advice, dosage recommendations, or encouragement for self-experimentation. All peptides offered by Iron Peak Peptides are intended for in vitro research, laboratory use, and institutional investigation only. Not for human consumption. Consult applicable regulations in your jurisdiction regarding the purchase and use of research peptides.
Related Research
Gene Expression and Regulation in Semax Research
Semaxβs influence on gene expression has emerged as a central theme in molecular neuroscience research, particularly in the context of brain injury and neurodegenerative diseases. As a synthetic analogue of adrenocorticotropic hormone (ACTH), Semax has demonstrated the ability to modulate the expression of a wide array of genes involved in the immune and vascular systemsβtwo critical domains for brain health and recovery following injury.
Molecular genetics studies have shown that Semax administration leads to significant changes in the expression levels of genes related to the innate immune system, including those that govern inflammatory processes and immune cell signaling. For example, transcriptomic analyses in rat brain tissues after ischemic stroke have revealed that peptide Semax upregulates genes involved in antigen presentation, cytokine signaling pathways, and immunoglobulin synthesis. These gene expression changes are believed to contribute to the peptideβs neuroprotective properties by orchestrating a more adaptive immune response and reducing detrimental inflammation in nervous tissues.
In addition to its effects on immune-related genes, Semax has been found to regulate genes associated with the vascular systems, supporting improved blood flow and tissue repair in models of cerebral ischemia. The peptideβs impact on receptor genes and other signaling pathways further underscores its multifaceted role in brain res and recovery. Notably, Semax administration has been shown to enhance the expression of neurotrophic factors such as brain-derived neurotrophic factor (BDNF), which is essential for neuronal survival, synaptic plasticity, and overall brain function.
These findings highlight the potential of Semax as a tool for modulating gene expression in the central nervous system, offering new avenues for therapeutic strategies targeting neurodegenerative diseases and ischemic injury. By influencing genes related to both the immune system and vascular systems, Semax contributes to a coordinated molecular response that supports neuroprotection and functional recovery.
Therapeutic Uses of Semax in Research and Clinical Context
The therapeutic potential of Semax has been extensively explored in both preclinical and clinical research, particularly for conditions involving acute brain injury and chronic neurodegeneration. As a synthetic peptide with robust neuroprotective properties, Semax has shown promise as a potential therapeutic agent in models of ischemic stroke, cerebral ischemia, and neurodegenerative diseases such as Alzheimerβs.
In animal studies of ischemic stroke, Semax administration has been associated with a marked reduction in infarct volume and a significant decrease in neuronal death within affected brain regions. These effects are attributed to the peptideβs ability to modulate the immune response, dampen inflammatory processes, and promote the survival of nerve tissue. The anti-inflammatory effects of Semax, combined with its capacity to regulate key signaling pathways involved in cell survival and repair, make it a compelling candidate for new therapeutic strategies aimed at improving outcomes after cerebral ischemia.
Beyond acute injury, Semax has also been investigated for its potential to slow the progression of neurodegenerative diseases. Research suggests that the peptideβs ability to enhance neurotrophic factor expression, reduce oxidative stress, and modulate immune system activity may help protect against the neuronal loss characteristic of conditions like Alzheimerβs disease. These neuroprotective effects, coupled with evidence of improved functional recovery in experimental models, underscore the broad therapeutic potential of Semax.
While much of the evidence to date comes from basic research and animal models, the promising results have spurred interest in further clinical studies to evaluate Semaxβs efficacy and safety in human populations. As research advances, Semax continues to stand out as a versatile synthetic peptide with significant potential for the development of innovative therapeutic strategies targeting both acute and chronic neurological disorders.
🔬 Explore Research Peptides
- Orforglipron 6mg β 100 Tablets — $279.00
- 5-Amino-1MQ 50mg (25 Tablets) — $85.00
- Adipotide 5mg — $69.00
- BPC-157/TB-500 Blend 10mg/10mg (20mg) — $110.00
